Literature DB >> 29063343

Acetaminophen clearance during ex vivo continuous renal replacement therapies.

Bridget A Scoville1, Vera Vulaj2, Bruce A Mueller2, Gail M Annich3, Deborah S Wagner4,5.   

Abstract

Intravenous acetaminophen is an adjuvant to opioid use in critically ill and surgical patients requiring continuous renal replacement therapy (CRRT). The objective of this study was to determine the ex vivo transmembrane clearance of intravenous acetaminophen during continuous hemofiltration and hemodialysis. Transmembrane clearance was assessed using a validated ex vivo bovine blood model for CRRT using an F8 or HF1400 hemodiafilter. Ultrafiltrate and dialysate flow rates were 1, 2, and 3 L/h. Urea and acetaminophen clearances were calculated and compared. Acetaminophen was readily cleared by continuous hemofiltration with both hemodiafilters. Acetaminophen clearance rates were 92-98% of ultrafiltrate production rates. Similarly, dialytic acetaminophen clearances approximated dialysate flow rates for both hemodiafilters. Acetaminophen is readily cleared by CRRT. Patients receiving CRRT and acetaminophen may require increased doses for adequate pain control.

Entities:  

Keywords:  Continuous renal replacement therapy; Critical care; Dialysisex vivo clearance; Intravenous acetaminophen

Mesh:

Substances:

Year:  2017        PMID: 29063343     DOI: 10.1007/s10047-017-1001-6

Source DB:  PubMed          Journal:  J Artif Organs        ISSN: 1434-7229            Impact factor:   1.731


  17 in total

1.  Is continuous veno-venous hemofiltration for acetaminophen-induced acute liver and renal failure worthwhile?

Authors:  R Agarwal; M O Farber
Journal:  Clin Nephrol       Date:  2002-02       Impact factor: 0.975

2.  Efficacy and safety of single and repeated administration of 1 gram intravenous acetaminophen injection (paracetamol) for pain management after major orthopedic surgery.

Authors:  Raymond S Sinatra; Jonathan S Jahr; Lowell W Reynolds; Eugene R Viscusi; Scott B Groudine; Catherine Payen-Champenois
Journal:  Anesthesiology       Date:  2005-04       Impact factor: 7.892

Review 3.  Antibiotic Dosing in Patients With Acute Kidney Injury: "Enough But Not Too Much".

Authors:  Susan J Lewis; Bruce A Mueller
Journal:  J Intensive Care Med       Date:  2014-10-16       Impact factor: 3.510

4.  Telavancin and hydroxy propyl-beta-cyclodextrin clearance during continuous renal replacement therapy: an in vitro study.

Authors:  Jignes H Patel; Marianne D Churchwell; Julie D Seroogy; Steven L Barriere; Maricor Grio; Bruce Mueller
Journal:  Int J Artif Organs       Date:  2009-10       Impact factor: 1.595

5.  The disposition of paracetamol and its conjugates during multiple dosing in patients with end-stage renal failure maintained on haemodialysis.

Authors:  U Martin; R M Temple; R J Winney; L F Prescott
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  In vitro clearance of intravenous acetaminophen in extracorporeal membrane oxygenation.

Authors:  A Gillogly; C Kilbourn; J Waldvogel; J Martin; G Annich; D Wagner
Journal:  Perfusion       Date:  2012-11-30       Impact factor: 1.972

7.  Medication dosing in critically ill patients with acute kidney injury treated with renal replacement therapy.

Authors:  Bridget A Scoville; Bruce A Mueller
Journal:  Am J Kidney Dis       Date:  2012-11-03       Impact factor: 8.860

8.  Ertapenem clearance during modeled continuous renal replacement therapy.

Authors:  J M Stevenson; J H Patel; M D Churchwell; A M Vilay; D D Depestel; F Sörgel; M Kinzig; V Jakob; B A Mueller
Journal:  Int J Artif Organs       Date:  2008-12       Impact factor: 1.595

9.  Antidote removal during haemodialysis for massive acetaminophen overdose.

Authors:  M L A Sivilotti; D N Juurlink; J S Garland; I Lenga; R Poley; L N Hanly; M Thompson
Journal:  Clin Toxicol (Phila)       Date:  2013-11       Impact factor: 4.467

10.  Determinants of postoperative acute kidney injury.

Authors:  Fernando José Abelha; Miguela Botelho; Vera Fernandes; Henrique Barros
Journal:  Crit Care       Date:  2009-05-22       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.